Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
Geodrill Announces Record First Quarter 2025 Financial Results (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News OmniAb Inc OABI

Healthcare Biotechnology
OmniAb, Inc. licenses discovery research technology to pharmaceutical and biotech companies and academic institutions to enable the discovery of therapeutics. Its technology platform creates and screens diverse antibody repertoires and is designed to identify optimal antibodies and other target-binding proteins for its partners’ drug development efforts. Central to the OmniAb platform... see more

Recent & Breaking News (NDAQ:OABI)

OmniAb to Report First Quarter 2023 Financial Results on May 11

Business Wire May 1, 2023

OmniAb to Participate in Upcoming Investor Conferences in May

Business Wire April 25, 2023

OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Business Wire March 30, 2023

OmniAb to Report Fourth Quarter 2022 Financial Results on March 30

Business Wire March 9, 2023

OmniAb to Participate in Three Upcoming Investor Conferences

Business Wire February 7, 2023

Hillstream BioPharma Announces Development of Proprietary Targeted Biologics, Knob Quatrabodies(TM) (HSB-1940) against PD-1, by combining Quatramers(TM) with OmniAb's Picobodies(TM), via a Collaboration Agreement, against Novel, Unreachable and Undruggable Epitopes in High Value Validated Targets

GlobeNewswire December 1, 2022

OmniAb Reports Third Quarter 2022 Financial Results and Business Highlights

Business Wire November 15, 2022

OmniAb Business Combination Approved by APAC Shareholders

Business Wire October 24, 2022

Avista Public Acquisition Corp. II Announces Effectiveness of Registration Statement and Sets Date for Extraordinary General Meeting to Vote on Proposed Business Combination

PR Newswire October 3, 2022

Ligand Announces that Janssen has Received Approval from European Commission for TECVAYLI® (teclistamab) for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma

Business Wire August 24, 2022

Ligand Reports Second Quarter 2022 Financial Results

Business Wire August 8, 2022

Ligand Reports First Quarter 2022 Financial Results

Business Wire May 4, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates NLSN, LHCG, AHPA

PR Newswire March 30, 2022

Moore Kuehn Encourages PLAN, HBP, Y, And AHPA Investors To Contact Law Firm

PR Newswire March 29, 2022

SHAREHOLDER NOTICE: Halper Sadeh LLP Investigates EMCF, RNER, PV, AHPA

PR Newswire March 24, 2022

Ligand to Spin-Off its OmniAb Business Through Merger with Avista Public Acquisition Corp. II

Business Wire March 23, 2022